WallStreetZenWallStreetZen

NASDAQ: SYRE
Spyre Therapeutics Inc Stock

$34.97+5.07 (+16.96%)
Updated Mar 4, 2024
SYRE Price
$34.97
Fair Value Price
N/A
Market Cap
$1.26B
52 Week Low
$2.66
52 Week High
$35.35
P/E
-0.71x
P/B
6.87x
P/S
167.52x
PEG
N/A
Dividend Yield
N/A
Revenue
$886.00k
Earnings
-$338.79M
Gross Margin
100%
Operating Margin
-38,241.08%
Profit Margin
-38,238.1%
Debt to Equity
0.4
Operating Cash Flow
-$100M
Beta
1.22
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

SYRE Overview

Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SYRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SYRE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SYRE is poor value based on its book value relative to its share price (6.87x), compared to the US Biotechnology industry average (6.2x)
P/B vs Industry Valuation
SYRE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SYRE due diligence checks available for Premium users.

Be the first to know about important SYRE news, forecast changes, insider trades & much more!

SYRE News

Valuation

SYRE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.71x
Industry
15.95x
Market
36.03x

SYRE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.87x
Industry
6.2x
SYRE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SYRE's financial health

Profit margin

Revenue
$0.0
Net Income
-$63.2M
Profit Margin
0%
SYRE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SYRE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$341.9M
Liabilities
$73.3M
Debt to equity
0.4
SYRE's short-term assets ($341.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SYRE's short-term assets ($341.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SYRE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SYRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$31.0M
Investing
-$35.3M
Financing
$163.6M
SYRE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SYRE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SYRE$1.26B+16.96%-0.71x6.87x
TARS$1.26B-0.16%-7.98x6.41x
MNKD$1.26B+3.33%-116.25x-5.11x
MGNX$1.29B+8.71%25.58x6.63x
ETNB$1.29B+9.11%-6.89x2.40x

Spyre Therapeutics Stock FAQ

What is Spyre Therapeutics's quote symbol?

(NASDAQ: SYRE) Spyre Therapeutics trades on the NASDAQ under the ticker symbol SYRE. Spyre Therapeutics stock quotes can also be displayed as NASDAQ: SYRE.

If you're new to stock investing, here's how to buy Spyre Therapeutics stock.

What is the 52 week high and low for Spyre Therapeutics (NASDAQ: SYRE)?

(NASDAQ: SYRE) Spyre Therapeutics's 52-week high was $35.35, and its 52-week low was $2.66. It is currently -1.07% from its 52-week high and 1,214.66% from its 52-week low.

How much is Spyre Therapeutics stock worth today?

(NASDAQ: SYRE) Spyre Therapeutics currently has 36,150,941 outstanding shares. With Spyre Therapeutics stock trading at $34.97 per share, the total value of Spyre Therapeutics stock (market capitalization) is $1.26B.

Spyre Therapeutics stock was originally listed at a price of $244.25 in Apr 7, 2016. If you had invested in Spyre Therapeutics stock at $244.25, your return over the last 7 years would have been -85.68%, for an annualized return of -24.25% (not including any dividends or dividend reinvestments).

How much is Spyre Therapeutics's stock price per share?

(NASDAQ: SYRE) Spyre Therapeutics stock price per share is $34.97 today (as of Mar 4, 2024).

What is Spyre Therapeutics's Market Cap?

(NASDAQ: SYRE) Spyre Therapeutics's market cap is $1.26B, as of Mar 5, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Spyre Therapeutics's market cap is calculated by multiplying SYRE's current stock price of $34.97 by SYRE's total outstanding shares of 36,150,941.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.